Insulin Lispro

Which is an analog insulin produced in a laboratory using recombinant DNA technology.

Insulin Lispro

Insulin-lispro; Insulin lispro [USAN:BAN:INN]; AM000966

Humalog pen, Humalog kwikpen

NA

NA

The dosage must be individualized. SC- The total daily insulin requirement may vary and is usually between 0.5 to 1 unit/kg/day.

For the treatment of Type 1 or 2 diabetes mellitus. To be used in conjunction with intermediate or long-acting insulin except when used in continuous insulin infusion pump.

Flu syndrome, inflammation of pharynx, nose, headache, pain, increased cough , infection, nausea, accidental injury, fever, abdominal pain, weakness, diarrhea, painful menstrual period, muscle pain, and urinary tract infection.

• Insulin Lispro can interact with reserpine, clonidipine, albuterol, beta-blockers such as timolol, metoprolol, labetalol, atenolol and nadolol.
• Direct exposure of Insulin Lispro to sunlight can result in degradation of insulin molecules.
• Do not consume alcohol while receiving Insulin Lispro. It can result in serious form of hypoglycemia. 

• Insulin Lispro is contraindicated in patients with hepatic or renal diseases. 
• Contraindicated in patients with an episode of low blood sugar, and hypersensitivity.

Store at 20-25°C.

Molecular weight

5808.0 Da

Molecular formula

C257H387N65O76S6

CAS number

133107-64-9

Precautions

An adjusted dosage may be needed in diabetic patients who are on oral anti-diabetic drugs.